Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Mar 30, 2026 · 10-K · 89 days after period end · 0001213900-26-036504
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$5.94M | -$6.65M | -$9.32M | -$10.65M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 30, 2026 · 89 d after period end
